房颤积极危险因素减少研究:对消融结局的影响——ARREST-AF随机临床试验
ARREST-AF多中心随机试验纳入122例BMI≥27且合并至少1项心血管代谢危险因素的 symptomatic 非永久性房颤首次消融患者,比较生活方式与危险因素管理(LRFM)与常规护理。
要点
- 房颤消融患者BMI≥27且合并代谢危险因素时,结构化危险因素管理可降低12个月复发风险。
- LRFM组体重、腰围、收缩压及症状严重度均较对照组显著改善。
核心结论
- 在BMI≥27且合并至少1项心血管代谢危险因素的房颤患者中,积极危险因素管理可减少导管消融后12个月内的心律失常复发。
- 该结果支持生活方式与危险因素管理对消融后维持窦性心律的重要性。
研究设计与样本
- 开放标签、多中心随机临床试验,2014年7月至2018年9月在南澳大利亚阿德莱德3个中心开展,随访12个月。
- 纳入连续的非永久性症状性房颤首次导管消融患者,BMI≥27且至少1项额外心血管代谢危险因素,共122例(平均年龄60岁,男性82例占67%,平均BMI 33)。
- 按1:1随机分为生活方式与危险因素管理组(LRFM,62例)和常规护理组(60例),两组均接受指南导向的房颤管理并由盲法团队随访。
- LRFM组在结构化、医生主导的定制门诊接受管理;常规护理组由治疗医生提供危险因素管理信息但未入组该门诊。
- 所有患者均行肺静脉隔离,电生理医生酌情追加消融。
主要发现
- 12个月复发性心律失常的风险比LRFM组相对于常规护理组为0.53(95%CI 0.32-0.89)。
- LRFM组房颤症状严重度较对照组显著改善,平均差-2.0(95%CI -3.7至-0.3)。
- 12个月时LRFM组体重较对照组低9.0 kg(95%CI -11.1至-6.8 kg),腰围低7.0 cm(95%CI -9.4至-4.5 cm)。
- 12个月时LRFM组收缩压较对照组低10.8 mm Hg(95%CI -16.1至-5.5 mm Hg),舒张压差异无统计学意义(-3.5 mm Hg,95%CI -7.2至0.2 mm Hg)。
临床怎么用
- 对BMI≥27且合并心血管代谢危险因素的房颤消融患者,可考虑转介结构化危险因素管理门诊以改善消融结局。
- 危险因素管理应涵盖体重、腰围、血压等可调控指标,并作为消融围术期综合管理的一部分。
局限性
- 开放标签设计,样本量较小(122例),随访12个月。
- 结果来自3个中心,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial fibrillation (AF) ablation outcomes demonstrate attrition over time. Although observational studies have reported reduced arrhythmia recurrence after AF ablation with aggressive lifestyle and risk factor modification, evidence from randomized clinical trials is lacking. OBJECTIVE: To determine the impact of risk factor and weight management on AF ablation rhythm outcomes. DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, multicenter, randomized clinical trial with 12-month follow-up conducted from July 2014 to September 2018. The setting included 3 sites in Adelaide, South Australia. Included in the analysis were consecutive patients with nonpermanent symptomatic AF undergoing first-time catheter ablation with a body mass index (BMI) greater than or equal to 27 (calculated as weight in kilograms divided by height in meters squared) and 1 or more additional cardiometabolic risk factors. Data were analyzed from September 2023 to August 2024. INTERVENTIONS: Patients were randomized 1:1 to lifestyle and risk factor management (LRFM) or usual care (UC) at catheter ablation. The LRFM group was treated in a structured, physician-led tailored clinic to reduce modifiable risk factors. The UC group was given information on management of risk factors by their treating physician but were not enrolled into the risk factor modification clinic. Both groups received guideline-directed care for management of AF by a team blinded to randomization. Pulmonary vein isolation was undertaken in each patient with additional ablation considered at the discretion of the electrophysiologist. MAIN OUTCOMES AND MEASURES: Proportion of patients free from AF in the 12-month period after ablation. RESULTS: Of 122 participants (mean [SD] age, 60 [10] years; 82 male [67%]; mean [SD] BMI, 33 [5]), 62 were randomized to LRFM, and 60 were randomized to UC. Primary end point at 12 months after ablation was observed in 38 patients (61.3%) in the LRFM group and 24 (40%) in the control group (P = .03). The hazard for recurrent arrhythmia over 12 months was 0.53 (95% CI, 0.32-0.89) for LRFM vs UC. AF symptom severity was significantly improved in the LRFM group compared with the UC group (mean difference, -2.0; 95% CI, -3.7 to -0.3). Patients in the LRFM group achieved a significantly improved risk factor profile compared with those in the UC group (mean difference, body weight, -9.0 kg; 95% CI, -11.1 to -6.8 kg and waist circumference, -7.0 cm; 95% CI, -9.4 to -4.5 cm were lower at 12 months in the LRFM group; systolic BP was lower at 12 months in the LRFM group, -10.8 mm Hg; 95% CI, -16.1 to -5.5 mm Hg, although there was no difference in diastolic BP, -3.5 mm Hg; 95% CI, -7.2 to 0.2 mm Hg). CONCLUSIONS AND RELEVANCE: Among patients with AF, elevated BMI, and 1 or more additional cardiometabolic risk factors, aggressive risk factor management reduced arrhythmia recurrence over the 12-month period after catheter ablation. These findings demonstrate the importance of LRFM for the maintenance of sinus rhythm after catheter ablation. TRIAL REGISTRATION: ANZCTR Registry Identifier: ACTRN12613000444785.
引用
- Pathak RK, Elliott AD, Lau DH, et al. Aggressive Risk Factor Reduction Study for Atrial Fibrillation Implications for Ablation Outcomes: The ARREST-AF Randomized Clinical Trial. JAMA Cardiol. 2025. PMID: 41160038. doi:10.1001/jamacardio.2025.4007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。